The FDA has extended its review of a new version of Sanofi’s multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.
Rigel loses Lilly alliance in pharma industry’s latest RIPK exit
RIPK1 is becoming a relative desert for large drugmakers. Eli Lilly has joined the exodus, ripping apart the remainder of its up to $960 million
